297 related articles for article (PubMed ID: 19203843)
1. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
3. Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.
Lee N; Schoder H; Beattie B; Lanning R; Riaz N; McBride S; Katabi N; Li D; Yarusi B; Chan S; Mitrani L; Zhang Z; Pfister DG; Sherman E; Baxi S; Boyle J; Morris LG; Ganly I; Wong R; Humm J
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):9-17. PubMed ID: 27511842
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
[TBL] [Abstract][Full Text] [Related]
5. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
[TBL] [Abstract][Full Text] [Related]
6. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
7. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.
Yasuda K; Onimaru R; Okamoto S; Shiga T; Katoh N; Tsuchiya K; Suzuki R; Takeuchi W; Kuge Y; Tamaki N; Shirato H
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):142-7. PubMed ID: 22583608
[TBL] [Abstract][Full Text] [Related]
8. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.
Henriques de Figueiredo B; Zacharatou C; Galland-Girodet S; Benech J; De Clermont-Gallerande H; Lamare F; Hatt M; Digue L; De Mones del Pujol E; Fernandez P
Strahlenther Onkol; 2015 Mar; 191(3):217-24. PubMed ID: 25245468
[TBL] [Abstract][Full Text] [Related]
10. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Gagel B; Reinartz P; Demirel C; Kaiser HJ; Zimny M; Piroth M; Pinkawa M; Stanzel S; Asadpour B; Hamacher K; Coenen HH; Buell U; Eble MJ
BMC Cancer; 2006 Mar; 6():51. PubMed ID: 16515707
[TBL] [Abstract][Full Text] [Related]
11. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.
Hicks RJ; Rischin D; Fisher R; Binns D; Scott AM; Peters LJ
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1384-91. PubMed ID: 16133382
[TBL] [Abstract][Full Text] [Related]
12. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
Lin Z; Mechalakos J; Nehmeh S; Schoder H; Lee N; Humm J; Ling CC
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1219-28. PubMed ID: 18313529
[TBL] [Abstract][Full Text] [Related]
13. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
14. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
[TBL] [Abstract][Full Text] [Related]
17. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
Jansen JF; Schöder H; Lee NY; Wang Y; Pfister DG; Fury MG; Stambuk HE; Humm JL; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1403-10. PubMed ID: 19906496
[TBL] [Abstract][Full Text] [Related]
19. [18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.
Cheney MD; Chen YL; Lim R; Winrich BK; Grosu AL; Trofimov AV; Depauw N; Shih HA; Schwab JH; Hornicek FJ; DeLaney TF
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1030-6. PubMed ID: 25539367
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]